Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
LONDON, BOSTON, TOKYO, SAN FRANCISCO (February 28, 2018) — Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for smaller groups. In biopharma, drug approvals in the US jumped, the IPO window was thrown open and venture funding soared. However, concerns about the growth prospects of large drug developers led to a disappointing year for some big pharma groups. In the device sector M&A activity increased markedly and all the big players saw their share prices head skywards. However, it was a dismal story on the funding and IPO front, continuing a trend that has lasted for several years.
“Biopharma investors started 2017 hoping for a market recovery, and by the end of the year their wish had pretty much been granted. The worst fears about the economic impact of Donald Trump’s US presidency failed to materialise, and low-tax rhetoric ensured that by the end of the year the markets presented a picture of health,” said Amy Brown, author of the pharma and biotech section.
“In medtech the funding crunch still exists for small companies,” said Elizabeth Cairns, author of the medtech section. “Last year so few venture deals were done, and so few IPOs got away, that there is a real possibility that the pool of start-ups could dry up completely if this trend is not reversed.”
Other key findings include:
The report published today offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2017. The report is based on EvaluatePharma® and EvaluateMedTech® data. To download the report, please visit www.evaluate.com/2017Review.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provide thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.